Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Polycystic Ovary Syndrome 3Cardiotoxicity 2Breast Neoplasms 2Weight Gain 1Renal Insufficiency, Chronic 1Neoplasms 1Kidney Neoplasms 1Heart Failure 1Carcinoma, Renal Cell 1

Interventions

sacubitril and valsartan sodium hydrate drug combination 3Nutrition Assessment 3Exercise 3Carvedilol 3dapagliflozin 2Standard of Care 2Rituximab 2Ivabradine 2Control Groups 2Atorvastatin 2pertuzumab 1pegfilgrastim 1obinutuzumab 1nicotinamide-beta-riboside 1empagliflozin 1candesartan 1acalabrutinib 1Vincristine 1Valsartan 1Trastuzumab 1Surveys and Questionnaires 1Spironolactone 1Sodium Chloride 1Simendan 1Secondary Prevention 1Resistance Training 1Pyruvic Acid 1Prednisolone 1Practice Guidelines as Topic 1Population Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Heart Failure × empagliflozin × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡